Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
- Friday, May 27, 2022, 7:14
- Environment
- Add a comment
Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai’s Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients Presentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical…
About the Author
adminasapcorp has written 39761 stories on this site.